Cited 42 times in
Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: A multicentre, open label study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남궁기 | - |
dc.contributor.author | 신동환 | - |
dc.date.accessioned | 2015-06-10T12:28:00Z | - |
dc.date.available | 2015-06-10T12:28:00Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0278-5846 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/109853 | - |
dc.description.abstract | Major depressive disorder and alcohol dependence are common and serious mental illnesses. There is a great interest in discovering useful treatments for both mood symptoms and alcohol abuse in those patients with depressive disorders and comorbid alcohol dependence. The primary purpose of this study was to evaluate the effectiveness and tolerability of mirtazapine for the treatment of patients with alcohol dependence comorbid with a depressive disorder in an open label, naturalistic multicentre treatment setting. The 17-item Hamilton Depression Rating Scale (HDRS), the Hamilton Anxiety Rating Scale (HARS) and the Clinical Global Impression-Severity (CGI-S) scale were measured at baseline and at weeks 4 and 8 for the assessment of treatment effectiveness. Alcohol craving was measured using the Obsessive Compulsive Drinking Scale (OCDS) and the Visual Analog Scale for Craving (VAS). This study showed a statistically significant reduction of the scores on the HDRS (13.9 ± 7.3, p < 0.0001), HARS (10.8 ± 7.2, p < 0.0001) and the CGI-S (1.7 ± 1.0, p < 0.0001) from baseline to the endpoint (week 8). The OCDS and VAS scores were also decreased significantly by 42.3% and 53.2% (9.0 ± 10.0, p < 0.0001; 2.5 ± 2.4, p < 0.0001, respectively). The number of patients with a 50% reduction or more in the HDRS and HARS scores was 103 (72.0%) and 106 (74.1%) at the endpoint, respectively. Adverse events related to mirtazapine were observed in 10% or more of the patients in this study. In conclusion, the results from this naturalistic study suggest that the use of mirtazapine for the patients with alcohol dependence comorbid with depressive disorder is accompanied by clinical improvement in their mood and alcohol craving. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1196~1201 | - |
dc.relation.isPartOf | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Alcoholism/drug therapy* | - |
dc.subject.MESH | Alcoholism/epidemiology* | - |
dc.subject.MESH | Antidepressive Agents, Tricyclic/therapeutic use* | - |
dc.subject.MESH | Comorbidity | - |
dc.subject.MESH | Depressive Disorder/drug therapy* | - |
dc.subject.MESH | Depressive Disorder/epidemiology* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Mianserin/analogs & derivatives* | - |
dc.subject.MESH | Mianserin/therapeutic use | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mirtazapine | - |
dc.subject.MESH | Outcome Assessment (Health Care) | - |
dc.subject.MESH | Pain Measurement/methods | - |
dc.subject.MESH | Severity of Illness Index | - |
dc.subject.MESH | Time Factors | - |
dc.title | Mirtazapine for patients with alcohol dependence and comorbid depressive disorders: A multicentre, open label study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Psychiatry (정신과학) | - |
dc.contributor.googleauthor | Su-Jung Yoon | - |
dc.contributor.googleauthor | Chi-Un Pae | - |
dc.contributor.googleauthor | Dai-Jin Kim | - |
dc.contributor.googleauthor | Kee Namkoong | - |
dc.contributor.googleauthor | Eun Lee | - |
dc.contributor.googleauthor | Dong-Yul Oh | - |
dc.contributor.googleauthor | Young-Sik Lee | - |
dc.contributor.googleauthor | Dong-Hwan Shin | - |
dc.contributor.googleauthor | Young-Cheol Jeong | - |
dc.contributor.googleauthor | Joon-Hong Kim | - |
dc.contributor.googleauthor | Sung-Bin Choi | - |
dc.contributor.googleauthor | In-Bok Hwang | - |
dc.contributor.googleauthor | Young-Chul Shin | - |
dc.contributor.googleauthor | Sung-Nam Cho | - |
dc.contributor.googleauthor | Hae Kook Lee | - |
dc.contributor.googleauthor | Chung Tai Lee | - |
dc.identifier.doi | 10.1016/j.pnpbp.2006.02.018 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01240 | - |
dc.contributor.localId | A02098 | - |
dc.relation.journalcode | J02554 | - |
dc.identifier.eissn | 1878-4216 | - |
dc.identifier.pmid | 16624467 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S0278584606000777 | - |
dc.subject.keyword | Alcohol dependence | - |
dc.subject.keyword | CravingDepressive disorder | - |
dc.subject.keyword | Mirtazapine | - |
dc.contributor.alternativeName | Namkoong, Kee | - |
dc.contributor.alternativeName | Shin, Dong Hwan | - |
dc.contributor.affiliatedAuthor | Namkoong, Kee | - |
dc.contributor.affiliatedAuthor | Shin, Dong Hwan | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 30 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1196 | - |
dc.citation.endPage | 1201 | - |
dc.identifier.bibliographicCitation | PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, Vol.30(7) : 1196-1201, 2006 | - |
dc.identifier.rimsid | 50638 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.